Login to Your Account



Clinic Roundup


Thursday, December 9, 2010
• Bavarian Nordic AS, of Kvistgard, Denmark, reached a special protocol assessment agreement with the FDA for a Phase III registration study of Prostvac, an off-the-shelf therapeutic vaccine being developed under a cooperative research and development agreement with the National Cancer Institute, in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription